Low bone mineral density in children and adolescents with cancer
Authors:
Open Access
- 30 September 2020
- journal article
- review article
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 25 (3) , 137-144
Abstract
Maximizing accumulation of bone mass during childhood and adolescence is essential to attaining optimal peak bone mass. Childhood cancer survivors (CCS) have lower bone mineral density (BMD) than the general population. Chemotherapeutic agents including steroids and radiotherapy can affect BMD. Cancer itself, hormonal insufficiency, a poor nutritional state, and a deficit of physical activities during or after treatment also influence BMD in CCS, resulting in failure to achieve appropriate peak bone mass. Low BMD in childhood and adolescence can lead to osteoporosis in adult life and complications such as bone pain, bone deformity, and fractures. Thus, BMD in CCS should be monitored with appropriate intervention. Adequate intake of calcium and vitamin D and an increase in physical activity are recommended. Timely supplements of hormones are needed in some cases. Some publications have reported that bisphosphonate therapies using pamidronate or alendronate were well tolerated in CCS and helped increase BMD.Keywords
This publication has 62 references indexed in Scilit:
- Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood CancerJAMA, 2013
- Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinicsEuropean Journal of Endocrinology, 2013
- Factors Related to Decreased Bone Mineral Density in Childhood Cancer SurvivorsJournal of Korean Medical Science, 2013
- Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphomaBlood Research, 2013
- Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patientsBMC Musculoskeletal Disorders, 2010
- Addition of pamidronate to chemotherapy for the treatment of osteosarcomaCancer, 2010
- Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemiaHaematologica, 2009
- Growth Hormone, Insulin-Like Growth Factors, and the SkeletonEndocrine Reviews, 2008
- Bone health in children and adolescents after allogeneic stem cell transplantationCancer, 2007
- Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin’s lymphoma: results of a pilot studyJournal of Oncology Pharmacy Practice, 2005